ECSP13012609A - Composición farmacéutica - Google Patents
Composición farmacéuticaInfo
- Publication number
- ECSP13012609A ECSP13012609A ECSP13012609A ECSP13012609A EC SP13012609 A ECSP13012609 A EC SP13012609A EC SP13012609 A ECSP13012609 A EC SP13012609A EC SP13012609 A ECSP13012609 A EC SP13012609A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical composition
- antibodies
- therapeutic
- compositions
- treatment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 102000013498 tau Proteins Human genes 0.000 abstract 1
- 108010026424 tau Proteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10186810 | 2010-10-07 | ||
| EP11174248 | 2011-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012609A true ECSP13012609A (es) | 2013-07-31 |
Family
ID=44947048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012609 ECSP13012609A (es) | 2010-10-07 | 2013-05-07 | Composición farmacéutica |
Country Status (29)
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10266585B2 (en) * | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| US9304138B2 (en) * | 2010-10-07 | 2016-04-05 | Katholieke Universiteit Leuven | Pharmaceutical composition |
| PT2627672T (pt) | 2010-10-11 | 2018-11-16 | Univ Zuerich | Anticorpos anti-tau humanos |
| EP2670434B1 (en) * | 2011-01-31 | 2018-12-26 | Tau Bio-Logic Corp. | Treatment of tauopathies |
| GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| EP2747778B1 (en) | 2011-08-26 | 2017-12-06 | Wisconsin Alumni Research Foundation | Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
| EP3135689B1 (en) | 2011-10-07 | 2018-12-19 | AC Immune S.A. | Phosphospecific antibodies recognising tau |
| UA114902C2 (uk) | 2011-12-20 | 2017-08-28 | Янссен Байотек, Інк. | Виділене антитіло, яке зв'язує парний спіральний філамент-тау (псф-тау), та фармацевтична композиція, що містить таке антитіло |
| KR102132041B1 (ko) | 2012-04-05 | 2020-07-09 | 에이씨 이뮨 에스.에이. | 인간화된 타우 항체 |
| KR20200013072A (ko) * | 2012-07-03 | 2020-02-05 | 워싱턴 유니버시티 | Tau에 대한 항체 |
| WO2014016737A1 (en) * | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
| AU2013302540B2 (en) * | 2012-08-16 | 2018-02-15 | Ipierian, Inc. | Methods of treating a tauopathy |
| US12024568B2 (en) | 2012-09-13 | 2024-07-02 | Cornell University | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| AU2013361107B2 (en) * | 2012-12-21 | 2018-08-23 | Biogen International Neuroscience Gmbh | Human anti-tau antibodies |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| KR102233349B1 (ko) * | 2013-03-15 | 2021-03-31 | 에이씨 이뮨 에스.에이. | 항-타우(tau) 항체 및 사용 방법 |
| NZ714765A (en) | 2013-06-06 | 2021-12-24 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
| GB201312226D0 (en) * | 2013-07-08 | 2013-08-21 | Adx Neurosciences | Improved antibodies |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| WO2015081085A2 (en) * | 2013-11-27 | 2015-06-04 | Ipierian, Inc. | Methods of treating a tauopathy |
| SG11201605044RA (en) | 2013-12-20 | 2016-07-28 | Hoffmann La Roche | HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE |
| JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン，インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| CA2962969C (en) | 2014-09-30 | 2023-03-21 | Washington University | Tau kinetic measurements |
| WO2016079597A1 (en) * | 2014-11-19 | 2016-05-26 | Axon Neuroscience Se | Humanized tau antibodies in alzheimer's disease |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| TWI669314B (zh) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對ｔａｕ之抗體及其用途 |
| CA3258972A1 (en) | 2015-06-05 | 2025-04-17 | Ac Immune Sa | TAU ANTIBODIES AND METHODS OF USING THEM |
| WO2016207245A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
| WO2017005734A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| US10358503B2 (en) | 2015-08-13 | 2019-07-23 | New York University | Antibody-based molecules selective for the {P}Ser404 epitope of Tau and their uses in the diagnosis and treatment of tauopathy |
| EP3417056A1 (en) | 2016-02-19 | 2018-12-26 | Wisconsin Alumni Research Foundation (WARF) | Improved influenza b virus replication for vaccine development |
| PH12018502613B1 (en) | 2016-07-12 | 2023-02-01 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| JP2020511937A (ja) | 2016-12-07 | 2020-04-23 | ジェネンテック， インコーポレイテッド | 抗ｔａｕ抗体及び使用方法 |
| WO2018106781A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc | Anti-tau antibodies and methods of use |
| BR112018067721A2 (pt) * | 2017-01-04 | 2019-01-08 | H. Lundbeck A/S | anticorpos específicos para tau hiperfosforilada para o tratamento de doenças oculares |
| CN110520440A (zh) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | 抗τ抗体及其使用方法 |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| EA039569B1 (ru) * | 2017-03-14 | 2022-02-11 | Х. Лундбекк А/С | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
| JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| WO2018217630A1 (en) * | 2017-05-21 | 2018-11-29 | University Of Tennessee Research Foundation | Methods and compositions for targeting tissue lesions |
| TWI853617B (zh) | 2017-10-16 | 2024-08-21 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
| JP2021500891A (ja) | 2017-10-25 | 2021-01-14 | ウィスコンシン アルムニ リサーチ ファンデイション | 卵における複製のための安定化されたｈａを有する組換えインフルエンザウイルス |
| US11896680B2 (en) * | 2017-11-28 | 2024-02-13 | Mie University | Detection method |
| US12234280B2 (en) | 2018-03-05 | 2025-02-25 | Janssen Pharmaceutica Nv | Anti-PHF-tau antibodies and uses thereof |
| JP2021530552A (ja) | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| US11389523B2 (en) | 2018-08-20 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein |
| US12116415B2 (en) * | 2018-10-09 | 2024-10-15 | Single Cell Technology, Inc. | Anti-BCMA antibodies |
| AU2018446059A1 (en) * | 2018-10-17 | 2021-05-20 | The University Of Queensland | Methods and compositions for treating tauopathies |
| EP3877399A4 (en) | 2018-11-06 | 2022-10-19 | Alsatech, Inc. | CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES |
| US20220089768A1 (en) * | 2019-01-04 | 2022-03-24 | Trio Pharmaceuticals, Inc. | Multi-specific protein molecules and uses thereof |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| CN113874078B (zh) | 2019-04-05 | 2025-05-06 | Tauc3生物制品有限公司 | 抗tauc3抗体及其应用 |
| BR112021017046A2 (pt) * | 2019-04-12 | 2021-11-09 | Phanes Therapeutics Inc | Receptores de antígeno quiméricos antirreceptores de folato 1 humanizados e seus usos |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| CN112752251B (zh) | 2019-10-29 | 2022-05-06 | 中国移动通信有限公司研究院 | 一种ue标识符的分配方法、装置和计算机可读存储介质 |
| US11739303B2 (en) | 2020-01-24 | 2023-08-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized NA |
| KR20220137674A (ko) * | 2020-02-05 | 2022-10-12 | 스미토모 파마 가부시키가이샤 | 타우병증 및 인지증 관련 질환의 판정약 및 판정 방법 |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| CN116723856A (zh) | 2020-06-25 | 2023-09-08 | 默沙东有限责任公司 | 靶向丝氨酸413处磷酸化的tau的高亲和力抗体 |
| WO2022132923A1 (en) * | 2020-12-16 | 2022-06-23 | Voyager Therapeutics, Inc. | Tau binding compounds |
| EP4014997A1 (en) | 2020-12-16 | 2022-06-22 | Consejo Superior de Investigaciones Científicas (CSIC) | Stard1 inhibitors for the treatment of lysosomal disorders |
| EP4308154A1 (en) * | 2021-03-18 | 2024-01-24 | Seagen Inc. | Anti-alpp/alppl2 antibodies and antibody-drug conjugates |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| JP2025535203A (ja) | 2022-09-15 | 2025-10-23 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
| EP4658689A2 (en) * | 2023-02-02 | 2025-12-10 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Phosphomimetic mutants, phosphospecific antibodies, and uses thereof |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025128975A1 (en) * | 2023-12-14 | 2025-06-19 | Immunitas Therapeutics, Inc. | Cd161 binding proteins and related methods |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| DK0618968T3 (da) | 1991-12-06 | 2000-04-10 | Max Planck Gesellschaft | Midler til diagnostisering og behandling af Alzheimer's sygdom |
| JPH07509250A (ja) | 1992-07-27 | 1995-10-12 | アメリカ合衆国 | 血液脳バリヤーへのリポソームの標的化 |
| EP1076092A3 (en) | 1994-10-21 | 2001-03-28 | Innogenetics N.V. | Sequences of hepatitis C virus type10 and their use as prophylactic, therapeutic and diagnostic agents |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| WO1997034145A1 (fr) | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
| AU5508798A (en) * | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
| WO2002004949A2 (en) * | 2000-07-11 | 2002-01-17 | Molecular Geriatrics Corporation | Reagents and methods for identification of binding agents |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| WO2002017930A2 (en) | 2000-08-30 | 2002-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| JP4202250B2 (ja) | 2001-07-25 | 2008-12-24 | バイオマリン ファーマシューティカル インコーポレイテッド | 血液脳関門輸送を調節するための組成物および方法 |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| EP1581186A2 (en) | 2002-12-03 | 2005-10-05 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| EP1581203A1 (en) | 2002-12-24 | 2005-10-05 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| WO2005025511A2 (en) | 2003-09-10 | 2005-03-24 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| US7238788B2 (en) * | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| JP5173426B2 (ja) * | 2004-10-25 | 2013-04-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ａｄｄｌ抗体およびこの使用 |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20080220449A1 (en) | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
| EP2522351B1 (en) | 2007-06-13 | 2017-09-06 | Research Development Foundation | Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling |
| JPWO2009051220A1 (ja) * | 2007-10-19 | 2011-03-03 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| DK2408807T3 (da) * | 2009-03-18 | 2021-08-09 | Ac Immune Sa | Fremgangsmåde til terapeutisk anvendelse |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| JP5917394B2 (ja) * | 2009-06-10 | 2016-05-11 | ニューヨーク・ユニバーシティ | 病理学的タウタンパク質の免疫学的標的化方法 |
| AU2010277254B2 (en) | 2009-07-30 | 2015-05-07 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
| US9304138B2 (en) * | 2010-10-07 | 2016-04-05 | Katholieke Universiteit Leuven | Pharmaceutical composition |
-
2011
- 2011-10-07 US US13/500,608 patent/US9304138B2/en active Active
- 2011-10-07 HU HUE11773704A patent/HUE027649T2/en unknown
- 2011-10-07 AU AU2011311516A patent/AU2011311516B2/en active Active
- 2011-10-07 WO PCT/EP2011/067604 patent/WO2012045882A2/en not_active Ceased
- 2011-10-07 TW TW100136670A patent/TW201216985A/zh unknown
- 2011-10-07 BR BR112013008333-6A patent/BR112013008333B1/pt active IP Right Grant
- 2011-10-07 DK DK11773704.9T patent/DK2625198T3/en active
- 2011-10-07 JP JP2013532226A patent/JP6371526B2/ja active Active
- 2011-10-07 RU RU2013120544/10A patent/RU2603078C2/ru active
- 2011-10-07 ES ES11773704.9T patent/ES2548686T3/es active Active
- 2011-10-07 PE PE2013000800A patent/PE20140218A1/es not_active Application Discontinuation
- 2011-10-07 SG SG2013023031A patent/SG189136A1/en unknown
- 2011-10-07 CN CN201180058969.9A patent/CN103502272B/zh active Active
- 2011-10-07 CA CA2812865A patent/CA2812865C/en active Active
- 2011-10-07 SI SI201130615T patent/SI2625198T1/sl unknown
- 2011-10-07 PL PL11773704T patent/PL2625198T3/pl unknown
- 2011-10-07 MY MYPI2013700539A patent/MY164376A/en unknown
- 2011-10-07 KR KR1020137011715A patent/KR101988672B1/ko active Active
- 2011-10-07 MX MX2013003800A patent/MX338421B/es active IP Right Grant
- 2011-10-07 EP EP15177523.6A patent/EP2987807A3/en not_active Withdrawn
- 2011-10-07 PH PH1/2013/500615A patent/PH12013500615A1/en unknown
- 2011-10-07 EP EP11773704.9A patent/EP2625198B1/en active Active
- 2011-10-11 AR ARP110103735A patent/AR085198A1/es unknown
-
2013
- 2013-03-04 ZA ZA2013/02432A patent/ZA201302432B/en unknown
- 2013-04-04 IL IL225568A patent/IL225568A/en active IP Right Grant
- 2013-04-05 CO CO13089514A patent/CO6710903A2/es unknown
- 2013-04-05 CR CR20130160A patent/CR20130160A/es unknown
- 2013-04-08 CL CL2013000951A patent/CL2013000951A1/es unknown
- 2013-05-07 EC ECSP13012609 patent/ECSP13012609A/es unknown
-
2016
- 2016-02-17 US US15/045,804 patent/US10100104B2/en active Active
- 2016-04-25 HK HK16104710.3A patent/HK1216897A1/en unknown
-
2017
- 2017-01-20 JP JP2017008740A patent/JP2017113004A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012609A (es) | Composición farmacéutica | |
| AR092779A1 (es) | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau | |
| ECSP11011367A (es) | Composición farmacéutica | |
| CR20150016A (es) | Anticuerpo monoclonal | |
| AR092818A1 (es) | Anticuerpo tau humanizado | |
| CO6680687A2 (es) | Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas | |
| CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
| ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| CY1122987T1 (el) | Αντισωματα εναντι αμυλοειδους βητα | |
| GT201200313A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| UA115122C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським | |
| AR066987A1 (es) | Anticuerpo monoclonal contra proteina beta-amiloide | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| BR112014015851A2 (pt) | proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17 | |
| CL2008001960A1 (es) | Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide. | |
| CL2009000402A1 (es) | Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras. | |
| EA201170190A1 (ru) | Фармацевтическая композиция, содержащая экстракт мозга свиньи | |
| EA201291050A1 (ru) | Комбинация лекарств с протеинсвязывающими пролекарствами | |
| ECSP11010956A (es) | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos | |
| CO6602134A2 (es) | Proteinas de union a antigeno especificas para componente amiloide serico p | |
| BR112015003957A2 (pt) | alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria | |
| MX2021011596A (es) | Compuestos y composiciones como moduladores de se?alizacion tlr. | |
| BR112013000779A2 (pt) | composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial | |
| GB2473579A (en) | Stat3 and TYK2 as drug targets for neurodegenerative diseases |